DarioHealth (DRIO)
(Delayed Data from NSDQ)
$0.93 USD
+0.02 (2.10%)
Updated Aug 23, 2024 03:58 PM ET
After-Market: $0.92 -0.01 (-1.02%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for DarioHealth Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 28 | 21 | 8 | 8 |
Cost Of Goods | 14 | 18 | 17 | 5 | 5 |
Gross Profit | 6 | 10 | 4 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 62 | 66 | 80 | 32 | 20 |
Income After Depreciation & Amortization | -56 | -57 | -77 | -30 | -18 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 3 | 5 | 0 | 0 | 0 |
Pretax Income | -59 | -62 | -77 | -29 | -18 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -59 | -62 | -77 | -29 | -18 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -59 | -62 | -77 | -29 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -51 | -52 | -72 | -30 | -18 |
Depreciation & Amortization (Cash Flow) | 5 | 5 | 5 | 0 | 0 |
Income After Depreciation & Amortization | -56 | -57 | -77 | -30 | -18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 28.37 | 23.64 | 16.59 | 5.96 | 2.27 |
Diluted EPS Before Non-Recurring Items | -1.93 | -2.54 | -4.07 | -4.01 | -8.00 |
Diluted Net EPS (GAAP) | -1.93 | -2.54 | -4.07 | -4.01 | -8.00 |
Fiscal Year end for DarioHealth Corp falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 6.26 | 5.76 | 3.62 | 3.52 | 6.15 |
Cost Of Goods | 3.50 | 3.33 | 3.48 | 2.91 | 4.08 |
Gross Profit | 2.76 | 2.43 | 0.13 | 0.61 | 2.07 |
SG&A, R&D, and Dept/Amort Expenses | 18.95 | 20.29 | 14.35 | 16.16 | 16.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | -16.19 | -17.86 | -14.22 | -15.55 | -14.02 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | -2.58 | -8.69 | 0.01 | 0.19 | 2.57 |
Pretax Income | -13.61 | -9.17 | -14.22 | -15.73 | -16.59 |
Income Taxes | 0.00 | -1.99 | 0.06 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -13.61 | -7.18 | -14.29 | -15.73 | -16.59 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -13.61 | -7.18 | -14.29 | -15.73 | -16.59 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 39.83 | 34.44 | 37.82 | 28.82 | 28.19 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.20 | -0.41 | -0.49 | -0.58 |
Diluted Net EPS (GAAP) | -0.08 | -0.20 | -0.41 | -0.49 | -0.58 |